Juergen Barth
Impact in
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Lymphoma Diagnosis and Treatment 14
- Genetics 4
- Chronic Lymphocytic Leukemia Research 4
- Estrogen and related hormone effects 1
- Co-authors
- Mathias Rummel (14 shared papers)Wolfram Brugger (10 shared papers)Axel Hinke (8 shared papers)Manfred Welslau (8 shared papers)Christoph Losem (9 shared papers)Christina Balser (7 shared papers)Ulrich Kaiser (7 shared papers)Eckhart Weidmann (7 shared papers)
In The Last Decade
Juergen Barth
16 papers receiving 1.4k citations
Juergen Barth's Hit Papers
Peers
Comparison fields: 5 of 46
- Pathology and Forensic Medicine 1.2k
- Genetics 695
- Oncology 779
- Neurology 180
- Reproductive Medicine 72
Countries citing papers authored by Juergen Barth
This map shows the geographic impact of Juergen Barth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juergen Barth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juergen Barth more than expected).
Fields of papers citing papers by Juergen Barth
This network shows the impact of papers produced by Juergen Barth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juergen Barth. The network helps show where Juergen Barth may publish in the future.
Co-authors
The 25 scholars most cited alongside Juergen Barth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Hit paper breakdown → | 2013 | 985 |
| 2 | 2009 | 113 | |
| 3 | 2015 | 113 | |
| 4 | 2016 | 53 | |
| 5 | 2017 | 47 | |
| 6 | 2012 | 35 | |
| 7 | 2015 | 26 | |
| 8 | 2010 | 26 | |
| 9 | 2012 | 16 | |
| 10 | 2018 | 15 | |
| 11 | 2009 | 8 | |
| 12 | 2017 | 4 | |
| 13 | [Observations and results of a double-target experiment on the concept of multi-stage cancer therapy using healthy subjects]. | 1970 | 2 |
| 14 | 2009 | 1 | |
| 15 | 2012 | 1 | |
| 16 | 2011 | 1 | |
| 17 | 2011 | 1 |
About Juergen Barth
Juergen Barth is a scholar working on Pathology and Forensic Medicine, Genetics, Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 17 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (4 papers), Sarcoma Diagnosis and Treatment (1 paper), Estrogen and related hormone effects (1 paper), Prostate Cancer Treatment and Research (1 paper), Acute Lymphoblastic Leukemia research (1 paper), Renal cell carcinoma treatment (1 paper) and Mycobacterium research and diagnosis (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (1.2k citations), Genetics (695 citations), Oncology (779 citations), Neurology (180 citations) and Reproductive Medicine (72 citations). Juergen Barth has collaborated with scholars based in Germany, Austria and Estonia. Frequent co-authors include Mathias Rummel, Wolfram Brugger, Axel Hinke, Manfred Welslau, Christoph Losem, Christina Balser, Ulrich Kaiser, Eckhart Weidmann, N. Niederle and Georg Maschmeyer. Their work appears in journals such as Blood, Journal of Clinical Oncology, The Lancet Oncology, Annals of Hematology and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.